北京赛科希德科技股份有限公司 董事会审计委员会 2024 年度履职情况报告 根据《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规、规范 性文件及《公司章程》《董事会审计委员会工作细则》等公司相关制度的规定， 北京赛科希德科技股份有限公司（以下简称"公司"）董事会审计委员会本着勤 勉尽责的原则，积极开展工作，认真履行职责，现就 2024 年度履职情况报告如 下： 一、审计委员会基本情况 公司第三届董事会审计委员会由独立董事穆培林女士、独立董事赵锐女士和 独立董事姜哲铭先生共同组成，三名委员均未在公司担任高级管理人员，其中独 立董事过半数，主任委员由独立董事中会计专业人士穆培林女士担任。 董事会审计委员会委员任职均符合中国证监会、上海证券交易所的相关规定 及《公司章程》《董事会审计委员会工作细则》的规定。 二、审计委员会召开情况 报告期内，公司董事会审计委员会共召开会议 5 次，会议的组织、召开及表 决均符合相关法律法规及规范性文件和《公司章程》等相关规定。公司全体审计 委员会委员参加了各次会议，会议议案全部审议通过。具体审议情 ...

召开日期时间：2025 年 5 月 15 日 10 点 00 分 证券代码：688338 证券简称：赛科希德 公告编号：2025-018 北京赛科希德科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 召开地点：北京市大兴区百利街 19 号院公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 15 日 至2025 年 5 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年5月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 东大会召开当日的交易时间 ...

证券代码：688338 证券简称：赛科希德 公告编号：2025-013 北京赛科希德科技股份有限公司 第四届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 北京赛科希德科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日以现场方式召开第四届监事会第二次会议，本次会议通知于 2024 年 4 月 11 日以电子邮件形式送达公司全体监事，会议材料均在监事会会议召开前以电子邮 件形式提交全体监事。会议应当出席的监事 3 人，实际出席会议的监事 3 人，本 次会议由监事会主席张颖先生主持，公司部分高管列席了本次会议。本次监事会 会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的 规定。 二、 监事会会议审议情况 经与会监事审议表决，形成决议如下： 1.审议通过《关于<2024 年年度报告>及摘要的议案》 表决内容：公司按照相关规定编制的《2024 年年度报告》及《2024 年年度 报告摘要》。监事会认为：公司 2024 年年度报告的编制和审议程序 ...

证券代码：688338 证券简称：赛科希德 公告编号：2025-012 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 北京赛科希德科技股份有限公司 第四届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京赛科希德科技股份有限公司（以下简称"公司"） 于 2025 年 4 月 23 日在公司会议室以现场结合通讯方式召开第四届董事会第二次会议，本次会议通 知于 2025 年 4 月 11 日以电子邮件形式送达公司全体董事，会议材料均在董事会 会议召开前以电子邮件形式提交全体董事。本次会议应出席的董事 9 人，实际出 席会议的董事 9 人，会议由董事长吴仕明先生主持，公司监事及高级管理人员列 席了本次会议。本次董事会会议的召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定。 二、董事会会议审议情况 经与会董事审议表决，形成决议如下： 1. 审议通过《关于<2024 年年度报告>及摘要的议案》 表决内容：公司按照相关规定完成 ...

重要内容提示： 每股分配比例：每 10 股派发现金红利 3.3 元（含税），本次利润分配 不送红股，不进行资本公积转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本扣除回购专户 中的股份数为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 证券代码：688338 证券简称：赛科希德 公告编号：2025-014 北京赛科希德科技股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 （以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能 被实施其他风险警示的情形。 一、 利润分配方案内容 （一）利润分配方案的具体内容 截至 2024 年 12 月 31 日，公司母公司报表中期末未分配利润为人民币 518,672,304.45 元。经董事会决议，公司 2024 年年度 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥68,639,307.27, a decrease of 9.47% compared to ¥75,818,644.14 in the same period last year[3] - Net profit attributable to shareholders was ¥23,132,857.77, down 23.98% from ¥30,429,780.54 year-on-year[3] - Basic earnings per share were ¥0.22, a decline of 24.14% from ¥0.29 in the same period last year[3] - Operating profit for Q1 2025 was ¥27,407,416.83, a decline of 23.0% from ¥35,609,570.89 in Q1 2024[18] - The total comprehensive income for Q1 2025 was ¥23,108,241.65, a decrease from ¥30,416,910.80 in Q1 2024[19] - The net profit for Q1 2025 was CNY 23,395,608.73, down 28.0% from CNY 32,555,521.07 in Q1 2024[28] Cash Flow - The net cash flow from operating activities decreased by 74.61%, amounting to ¥5,030,276.60 compared to ¥19,814,813.86 in the previous year[3] - Cash flow from operating activities for Q1 2025 was ¥5,030,276.60, significantly lower than ¥19,814,813.86 in Q1 2024[21] - The company reported a net cash outflow from investing activities of ¥4,261,410.79 in Q1 2025, compared to an outflow of ¥39,848,101.52 in Q1 2024[22] - The net cash flow from operating activities was 2,345,009.28, a decrease from 19,887,136.35 in the previous period, indicating a decline of approximately 88.2%[31] - Total cash outflow from operating activities amounted to 68,464,291.73, compared to 66,608,569.44 previously, reflecting an increase of about 2.8%[31] - The ending balance of cash and cash equivalents was 988,647,671.51, down from 1,198,013,097.82, representing a decrease of approximately 17.5%[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,746,880,074.78, a slight decrease of 0.10% from ¥1,748,651,398.28 at the end of the previous year[4] - Total liabilities decreased to RMB 89,301,227.02 from RMB 102,460,350.24 as of December 31, 2024[15] - The total equity attributable to shareholders increased to RMB 1,657,682,710.97 from RMB 1,646,270,295.13 at the end of 2024[15] - The total assets amounted to CNY 1,778,906,949.10, slightly down from CNY 1,780,564,344.64 in the previous period[26] - The total liabilities decreased to CNY 117,372,101.81 from CNY 130,704,664.15, reflecting a reduction of approximately 10.2%[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,725[8] - The largest shareholder, Wu Shiming, holds 34.66% of the shares, totaling 36,787,960 shares[9] - As of March 31, 2025, the company has repurchased a total of 2,172,456 shares, accounting for 2.0467% of the total share capital[11] Research and Development - Research and development expenses totaled ¥4,499,882.03, representing 6.56% of operating revenue, an increase of 0.37 percentage points from the previous year[4] - Research and development expenses for Q1 2025 were ¥4,499,882.03, slightly down from ¥4,695,066.54 in Q1 2024[18] - The company's research and development expenses for Q1 2025 were CNY 4,855,595.69, slightly up from CNY 4,695,066.54 in Q1 2024[27] Other Financial Metrics - The weighted average return on equity was 1.40%, down 0.48 percentage points from 1.88% in the previous year[3] - Non-recurring gains and losses amounted to ¥921,556.04, with significant contributions from government subsidies and asset disposals[7] - The company reported a significant cash inflow of 201,060,273.98 related to investment activities, highlighting strong investment recovery efforts[31] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[31] - The company experienced a foreign exchange impact of -111,680.81 on cash and cash equivalents, reflecting currency fluctuations[31]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth[18]. - The company's operating revenue for 2024 reached ¥305,870,242.02, representing an increase of 11.03% compared to ¥275,486,908.66 in 2023[25]. - Net profit attributable to shareholders for 2024 was ¥112,999,583.01, a decrease of 3.35% from ¥116,912,526.98 in 2023[25]. - Basic earnings per share for 2024 were ¥1.07, down 2.73% from ¥1.10 in 2023[25]. - The weighted average return on equity for 2024 was 6.91%, a decrease of 0.63 percentage points from 7.54% in 2023[25]. - The net cash flow from operating activities for 2024 was ¥122,983,903.25, an increase of 12.17% compared to ¥109,643,413.03 in 2023[25]. - The company reported a total revenue of 124,017,000.00 RMB, with a net profit of 60,105,153.85 RMB, indicating a significant performance in the reporting period[80]. - The company’s net profit attributable to ordinary shareholders for the most recent fiscal year is approximately $113 million[182]. Dividend Distribution - The company plans to distribute a cash dividend of 3.3 RMB per 10 shares, totaling approximately 34.31 million RMB, which represents 30.36% of the net profit attributable to shareholders for the year[7]. - The company has not proposed any stock dividends or capital reserve transfers for this profit distribution[7]. - The company’s cash dividend for the 2023 fiscal year was approved, distributing 0.26 RMB per share, totaling 27,597,024 RMB[175]. - The cumulative cash dividends over the last three fiscal years total approximately $83 million, representing a cash dividend payout ratio of 74.67%[182]. Research and Development - Research and development investments increased by 30%, focusing on innovative technologies in the healthcare sector[18]. - The company invested ¥19,604,679.27 in R&D, reflecting a year-on-year increase of 2.23%[40]. - The total R&D investment accounted for 6.41% of operating revenue, a decrease of 0.55 percentage points compared to the previous year[73]. - The company is actively developing multiple projects, including coagulation testing instruments and diagnostic reagents, to enhance its product line in the thrombosis and hemostasis diagnostics field[84]. - The company has developed a core technology cluster covering instruments, reagents, and consumables, with 15 core technologies and 45 patents, including 14 invention patents as of December 31, 2024[58]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[18]. - The company provided a positive outlook for the next quarter, projecting a revenue growth of 20%[18]. - A new strategic partnership was announced, expected to enhance distribution channels and increase sales by 15%[18]. - The company plans to increase its marketing budget by 15% to support new product launches and market penetration[147]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[18]. Operational Efficiency and Cost Management - The company aims to improve operational efficiency, targeting a 5% reduction in costs by the end of the fiscal year[18]. - The management emphasized the importance of sustainability initiatives, planning to invest 100 million RMB in green technologies[18]. - The company aims to implement cost reduction and efficiency enhancement measures to ensure sustainable development amidst increasing competition and cost pressures[43]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[6]. - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has established specialized committees including the Audit Committee, Strategy Committee, Nomination Committee, and Compensation and Assessment Committee to oversee relevant matters[137]. - The company maintains independent operations in business, personnel, assets, institutions, and finance, ensuring no detrimental related party transactions[139]. Environmental Responsibility - The company actively promotes sustainable development and environmental protection while enhancing corporate governance[189][190]. - The wastewater generated during operations is treated and meets the discharge standards set by the relevant environmental regulations[200]. - The company has implemented air pollution control measures, ensuring that emissions from volatile organic compounds and acidic gases comply with the national standards[200]. - The company has established a comprehensive waste management system to handle both industrial and domestic waste effectively[199]. Employee and Management Information - The total number of employees in the parent company and major subsidiaries is 278, with 267 in the parent company and 11 in subsidiaries[169]. - The company has a diverse employee composition, including 116 sales personnel, 83 production personnel, and 54 technical personnel[170]. - The total compensation for R&D personnel was 983.07 million RMB, with an average salary of 21.85 million RMB, showing a slight increase from the previous average of 21.43 million RMB[82]. - The company has a structured process for determining the remuneration of directors and senior management, which includes performance assessments[154].

RSM | 容 诚 内部控制审计报告 北京赛科希德科技股份有限公司 容诚审字[2025]100Z1184 号 容诚会计 容诚会计师事务所(特殊普通合伙) 中国 · 北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.cmo.fgov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http:///cc.mot.gov.cn） 进行查询 内部控制审计报告 容诚审字[2025]100Z1184 北京赛科希德科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了北京赛科希德科技股份有限公司(以下简称"赛科希德公司")2024年 12 月 31 日的财务报告内部控制的有效性。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表 审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 四、财务报告内部控制审计意见 我们认为,赛科希德公司于 2024年 12月 31 日按照《企业内部控制基本规范》 和相关规定在所有重大方面保持了有效的财务报告内 ...

"假sM | 容 诚 募集资金存放与实际使用情况鉴证报告 北京赛科希德科技股份有限公司 容诚专字|2025|100Z0559 号 容诚会计师事务所(特殊普通合伙) 中国 · 北京 ， 募集资金存放与实际使用情况鉴证报告 容诚专字[2025]100Z0559 号 北京赛科希德科技股份有限公司全体股东: 我们审核了后附的北京赛科希德科技股份有限公司(以下简称"赛科希德公 司"）董事会编制的 2024年度《募集资金存放与实际使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 本鉴证报告仅供赛科希德公司年度报告披露之目的使用,不得用作任何其他 目的。我们同意将本鉴证报告作为赛科希德公司年度报告必备的文件,随其他文 件一起报送并对外披露。 二、 董事会的责任 按照中国证券监督管理委员会《上市公司监管指引第2号 -- 上市公司募集 资金管理和使用的监管要求》、上海证券交易所《上海证券交易所科创板上市公 司自律监管指引第1 号 -- 规范运作》编制《募集资金存放与实际使用情况的专 项报告》是赛科希德公司董事会的责任,这种责任包括保证其内容真实、准确、 完整,不存在虚假记录、误导性陈述或重大遗漏。 三、 注册会计师的 ...

" RSM | 容 诚 审计报告 北京赛科希德科技股份有限公司 容诚审字|2025|100Z1185 号 容诚会计J 容诚会计师事务所(特殊普通合伙) 中国 · 北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）" 进行数 " 进行业" 审 计 报 告 容诚审字[2025]100Z1185 号 北京赛科希德科技股份有限公司全体股东: 一、审计意见 我们审计了北京赛科希德科技股份有限公司(以下简称"赛科希德公司")财 务报表,包括 2024年12月 31日的合并及母公司资产负债表,2024年度的合并及 母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及 相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制, 公允反映了赛科希德公司 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并及母公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注 册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。 按照 ...